ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0128

Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck

Rosachiara Forcignanò1, Fiorella Anna Lombardi2, Mariangela Ciccarese3, Eugenio Quarta4, Antonella Grimaldi5, Laura Quarta5, Delia Ciardo2, Ernesto Casciaro2, Paola Pisani2, Francesco Conversano2, Maurizio Muratore5 and Sergio Casciaro2, 1O.U. of Oncology, “Sacro Cuore di Gesù” Hospital, Gallipoli, Lecce, Italy, Gallipoli, Italy, 2National Research Council, Institute of Clinical Physiology, Lecce, Italy, Lecce, Italy, 3O.U. of Oncology, “Vito Fazzi” Hospital, ASL-LE, Lecce, Italy, Lecce, Italy, 4O.U. of Rheumatology, "Galateo" Hospital, ASL-LE, San Cesario di Lecce, Lecce, Italy, San Cesario di Lecce, Italy, 5O.U. of Rheumatology, “Galateo” Hospital, San Cesario di Lecce ASL-LE, Lecce, Italy, San Cesario di Lecce, Italy

Meeting: ACR Convergence 2020

Keywords: Bone density, Clinical Osteoporosis, Hormone Replacement Therapy, Imaging, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Osteoporosis & Metabolic Bone Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The aim of the study was to carry out a short-term monitoring of the effect of aromatase inhibitors (AI) and Denosumab on bone health in post-menopausal women with breast cancer (BC) with positive estrogen receptor through a bone densitometry performed with Radiofrequency Echographic Multi-Spectrometry (REMS) and Dual-Energy X-ray Absorptiometry (DXA).

Methods: A group of patients (Group A) received AI adjuvant therapy annually and 60 mg Denosumab every 6 months. The other group (Group B) received annual AI therapy only. All patients underwent a femoral neck scan with REMS and DXA before receiving the first AI therapy (T0) and 12 months after (T1). Only REMS scans were repeated after additional 6 months (T2).

The results were analyzed in terms of relative changes in bone mineral density (BMD) compared to the basal value obtained at T0. The analysis of the results was carried out by balancing the two groups by age.

Results: The results of 200 patients were analyzed. As expected, for Group A (assuming Denosumab) an increasing trend in BMD was observed, whereas a decreasing trend in BMD was found for Group B both with REMS and DXA.

The difference between REMS and DXA obtained for patients in each group at each time point was not statistically significant. Instead, the difference between Group A and Group B is statistically significant for DXA (at T1) and REMS (at T1 and T2).

Conclusion: The effect of Denosumab in reducing the risk of fracture in BC patients treated with AIs is well known. The densitometric techniques currently available are not able to monitor BMD in the short term, since the minimum time between two consecutive measurements is at least 1 year [1]. REMS technology, on the other hand, has demonstrated high performance in terms of precision and repeatability of BMD measurement, and the consequent low least significant change (LSC) value [2]: consequently, it might overcome the limit of current densitometric techniques, allowing a repeated exam at 6 months. The results of this study demonstrate the feasibility of short-term follow-up using REMS technology with femoral neck scans.


Disclosure: R. Forcignanò, None; F. Lombardi, None; M. Ciccarese, None; E. Quarta, None; A. Grimaldi, None; L. Quarta, None; D. Ciardo, None; E. Casciaro, None; P. Pisani, None; F. Conversano, None; M. Muratore, None; S. Casciaro, None.

To cite this abstract in AMA style:

Forcignanò R, Lombardi F, Ciccarese M, Quarta E, Grimaldi A, Quarta L, Ciardo D, Casciaro E, Pisani P, Conversano F, Muratore M, Casciaro S. Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/short-term-monitoring-of-denosumab-effect-in-breast-cancer-patients-receiving-aromatase-inhibitors-using-radiofrequency-echographic-multi-spectrometry-rems-technology-on-femoral-neck/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/short-term-monitoring-of-denosumab-effect-in-breast-cancer-patients-receiving-aromatase-inhibitors-using-radiofrequency-echographic-multi-spectrometry-rems-technology-on-femoral-neck/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology